| Recruiting | Studying TAK-243 in Patients With Advanced Cancer NCT06223542 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Recruiting | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893 | Chinese PLA General Hospital | Phase 2 |
| Recruiting | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas NCT05279300 | CStone Pharmaceuticals | Phase 1 |
| Withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ an NCT06400264 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | First in Human, Dose Escalation Study of AN4005 NCT04999384 | Adlai Nortye Biopharma Co., Ltd. | Phase 1 |
| Terminated | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma NCT04609579 | Stingthera, Inc. | Phase 1 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Hae NCT04470947 | Medical University of Vienna | — |
| Active Not Recruiting | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol NCT06400251 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Sub NCT06400225 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H NCT06400238 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MAT NCT06308822 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) NCT05490771 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A NCT06385483 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification NCT06390839 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) NCT04439227 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subp NCT06385496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z NCT06390852 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATC NCT06390865 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol NCT06390826 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol NCT06357975 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MAT NCT06360575 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol NCT04439344 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) NCT04439240 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification ( NCT04439201 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) NCT04439123 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subproto NCT04439214 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N NCT04439149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotoco NCT04439188 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subp NCT04439357 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-S NCT04439175 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) NCT04439305 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1 NCT04439318 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant NCT06357988 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) NCT06303167 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subp NCT04439331 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R NCT04439279 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) NCT04439136 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) NCT04439266 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATC NCT04439110 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G NCT04439253 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATC NCT04439292 | National Cancer Institute (NCI) | Phase 2 |